Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Ozempic maker Novo Nordisk NOVO.B-0.35%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Novo Nordisk (NVO) stock falls as the company CEO Lars Fruergaard Jørgensen steps down after 8 years of leadership marked by surging profits & sales. Read more here.

The climb. In June 2024, the company was trading at a high of more than $140 per share, and the stock is up nearly 107% in the past five years. Read more about Novo Nordisk's stock moves and today ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound. Vandana Singh Circle Internet, Hims ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...